

Ute Katharina Bartels

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8192352/publications.pdf>

Version: 2024-02-01

177
papers

7,590
citations

101543

36
h-index

58581

82
g-index

180
all docs

180
docs citations

180
times ranked

8153
citing authors

#	ARTICLE	IF	CITATIONS
1	SIOP PODCâ€‘adapted treatment guidelines for craniopharyngioma in lowâ€‘and middleâ€‘income settings. Pediatric Blood and Cancer, 2023, 70, e28493.	1.5	8
2	Radiomic Features Based on MRI Predict Progression-Free Survival in Pediatric Diffuse Midline Glioma/Diffuse Intrinsic Pontine Glioma. Canadian Association of Radiologists Journal, 2023, 74, 119-126.	2.0	6
3	Characteristics of patients â€‘10 years of age with diffuse intrinsic pontine glioma: a report from the International DIPG/DMG Registry. Neuro-Oncology, 2022, 24, 141-152.	1.2	9
4	Accuracy of central neuro-imaging review of DIPG compared with histopathology in the International DIPG Registry. Neuro-Oncology, 2022, 24, 821-833.	1.2	9
5	EANO, SNO and Euracan consensus review on the current management and future development of intracranial germ cell tumors in adolescents and young adults. Neuro-Oncology, 2022, 24, 516-527.	1.2	60
6	Phase II trial of response-based radiation therapy for patients with localized germinoma: a Childrenâ€™s Oncology Group study. Neuro-Oncology, 2022, 24, 974-983.	1.2	30
7	A Phase 2 Trial of Response-Based Radiation Therapy for Localized Central Nervous System Germ Cell Tumors: Patterns of Failure and Radiation Dosimetry for Nongerminomatous Germ Cell Tumors. International Journal of Radiation Oncology Biology Physics, 2022, 113, 143-151.	0.8	7
8	Pediatric Brain Tumor Survivorsâ€™ Understanding of Friendships: A Qualitative Analysis of ADOS-2 Interview Responses. Journal of Pediatric Psychology, 2022, , .	2.1	2
9	Pattern of treatment failures in patients with central nervous system non-germinomatous germ cell tumors (CNS-NGGCT): A pooled analysis of clinical trials. Neuro-Oncology, 2022, 24, 1950-1961.	1.2	12
10	Impact of home-based cognitive or academic intervention on working memory and mathematics outcomes in pediatric brain tumor survivors: the Keys to Succeed pilot randomized controlled clinical trial. Child Neuropsychology, 2022, 28, 1116-1140.	1.3	3
11	Building the ecosystem for pediatric neuroâ€‘oncology care in Pakistan: Results of a 7â€‘year long twinning program between Canada and Pakistan. Pediatric Blood and Cancer, 2022, 69, e29726.	1.5	4
12	Imaging response assessment for CNS germ cell tumours: consensus recommendations from the European Society for Paediatric Oncology Brain Tumour Group and North American Children's Oncology Group. Lancet Oncology, The, 2022, 23, e218-e228.	10.7	4
13	Characteristics of children â€‘36 months of age with DIPG: A report from the international DIPG registry. Neuro-Oncology, 2022, 24, 2190-2199.	1.2	4
14	Optic Pathway Glioma in Children with Neurofibromatosis Type 1: A Multidisciplinary Entity, Posing Dilemmas in Diagnosis and Management Multidisciplinary Management of Optic Pathway Glioma in Children with Neurofibromatosis Type 1. Frontiers in Surgery, 2022, 9, 886697.	1.4	4
15	GCT-04. Pattern of Treatment Failures in Central Nervous System Non-Germinomatous Germ Cell Tumors (CNS-NGGCT): A Pooled Analysis of Clinical Trials. Neuro-Oncology, 2022, 24, i54-i54.	1.2	0
16	SURG-12. Endoscopic evaluation of ventricular dissemination in primary central nervous system (CNS) germ cell tumors (GCTs). Neuro-Oncology, 2022, 24, i144-i144.	1.2	0
17	GCT-02. Imaging response assessment for Central Nervous System Germ Cell Tumours: consensus recommendations from the European Society for Paediatric Oncology Brain Tumour Group (SIOPE-BTG) and North American Childrenâ€™s Oncology Group (COG). Neuro-Oncology, 2022, 24, i53-i54.	1.2	0
18	GCT-18. Endoscopic third ventriculostomy (ETV) and tumor biopsy are not associated with relapse rate or patterns in primary central nervous system (CNS) germ cell tumor (GCT). Neuro-Oncology, 2022, 24, i58-i58.	1.2	1

#	ARTICLE	IF	CITATIONS
19	IMMU-08. Nivolumab with or without ipilimumab in pediatric patients with high-grade CNS malignancies: efficacy, safety, biomarker, and pharmacokinetic results from Checkmate 908. Neuro-Oncology, 2022, 24, i82-i83.	1.2	3
20	IMG-08. Response assessment for pediatric craniopharyngioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. Neuro-Oncology, 2022, 24, i78-i78.	1.2	0
21	GCT-05. Multi-institutional analysis of treatment modalities in metastatic germinoma in children. Neuro-Oncology, 2022, 24, i54-i55.	1.2	0
22	GCT-22. OUTCOMES OF CHILDREN WITH LOCALIZED AND METASTATIC GERMINOMA TREATED WITH CHEMOTHERAPY FOLLOWED BY RADIATION THERAPY WITHOUT PRIMARY TUMOR BOOST. Neuro-Oncology, 2022, 24, i59-i59.	1.2	2
23	LINC-22. Primary central nervous system (CNS) germ cell tumors (GCT) in Central America and the Caribbean region: an AHOPCA 20-year experience. Neuro-Oncology, 2022, 24, i167-i167.	1.2	0
24	Salvage chemotherapy after failure of targeted therapy in a child with BRAF V600E low-grade glioma. Pediatric Blood and Cancer, 2021, 68, e28561.	1.5	2
25	Early signs of metabolic syndrome in pediatric central nervous system tumor survivors after high-dose chemotherapy and autologous stem-cell transplantation and radiation. Child's Nervous System, 2021, 37, 1087-1094.	1.1	1
26	Diagnostic discrepancies between antemortem clinical diagnosis and autopsy findings in pediatric cancer patients. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 478, 1179-1185.	2.8	3
27	Family environment as a predictor and moderator of cognitive and psychosocial outcomes in children treated for posterior fossa tumors. Child Neuropsychology, 2021, 27, 641-660.	1.3	6
28	Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma. Journal of Clinical Oncology, 2021, 39, 807-821.	1.6	40
29	Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03). Journal of Clinical Oncology, 2021, 39, 822-835.	1.6	106
30	Evaluation of the Pediatric Neuro-Oncology Resources Available in Chile. JCO Global Oncology, 2021, 7, 425-434.	1.8	3
31	Long-term medical imaging use in children with central nervous system tumors. PLoS ONE, 2021, 16, e0248643.	2.5	2
32	Follow-up evaluation of a web-based pediatric brain tumor board in Latin America. Pediatric Blood and Cancer, 2021, 68, e29073.	1.5	7
33	Multi-institutional analysis of treatment modalities in basal ganglia and thalamic germinoma. Pediatric Blood and Cancer, 2021, 68, e29172.	1.5	3
34	Selumetinib for optic pathway glioma: Seeing through the fog, (not yet) the end of the tunnel?. Neuro-Oncology, 2021, 23, 1627-1628.	1.2	3
35	Paediatric atypical choroid plexus papilloma: is adjuvant therapy necessary?. Journal of Neuro-Oncology, 2021, 155, 63-70.	2.9	6
36	Clinical phenotypes and prognostic features of embryonal tumours with multi-layered rosettes: a Rare Brain Tumor Registry study. The Lancet Child and Adolescent Health, 2021, 5, 800-813.	5.6	12

#	ARTICLE	IF	CITATIONS
37	Hearing Loss After Radiation and Chemotherapy for CNS and Head-and-Neck Tumors in Children. Journal of Clinical Oncology, 2021, 39, 3813-3821.	1.6	11
38	Hearing loss and intellectual outcome in children treated for embryonal brain tumors: Implications for young children treated with radiation sparing approaches. Cancer Medicine, 2021, 10, 7111-7125.	2.8	8
39	Ventricular size determination and management of ventriculomegaly and hydrocephalus in patients with diffuse intrinsic pontine glioma: an institutional experience. Journal of Neurosurgery, 2021, 135, 1139-1145.	1.6	3
40	A Novel Approach to Understanding Social Behaviors in Pediatric Brain Tumor Survivors: A Pilot Study. Journal of Pediatric Psychology, 2021, 46, 80-90.	2.1	5
41	Successful management of symptomatic hydrocephalus using a temporary external ventricular drain with or without endoscopic third ventriculostomy in pediatric patients with germinoma. Journal of Neurosurgery, 2021, , 1-6.	1.6	2
42	Executive functions and social skills in pediatric brain tumor survivors. Applied Neuropsychology: Child, 2020, 9, 83-91.	1.4	13
43	Intracranial Germ Cell Tumors in Adolescents and Young Adults: A 40-Year Multi-Institutional Review of Outcomes. International Journal of Radiation Oncology Biology Physics, 2020, 106, 269-278.	0.8	38
44	In Reply to Byun etÂal. International Journal of Radiation Oncology Biology Physics, 2020, 106, 219-220.	0.8	0
45	Indolent course of brainstem tumors with K27Mâ€H3.3 mutation. Pediatric Blood and Cancer, 2020, 67, e28102.	1.5	4
46	Neuropsychological impact of trametinib in pediatric lowâ€grade glioma: A case series. Pediatric Blood and Cancer, 2020, 67, e28690.	1.5	2
47	Long term toxicity of intracranial germ cell tumor treatment in adolescents and young adults. Journal of Neuro-Oncology, 2020, 149, 523-532.	2.9	14
48	Pontine gliomas a 10-year population-based study: a report from The Canadian Paediatric Brain Tumour Consortium (CPBTC). Journal of Neuro-Oncology, 2020, 149, 45-54.	2.9	8
49	Causes of death in pediatric neuro-oncology: the sickkids experience from 2000 to 2017. Journal of Neuro-Oncology, 2020, 149, 181-189.	2.9	10
50	Bevacizumab for pediatric radiation necrosis. Neuro-Oncology Practice, 2020, 7, 409-414.	1.6	9
51	Development of paediatric non-stage prognosticator guidelines for population-based cancer registries and updates to the 2014 Toronto Paediatric Cancer Stage Guidelines. Lancet Oncology, The, 2020, 21, e444-e451.	10.7	15
52	ETMR-22. TITLE: DEFINING THE CLINICAL AND PROGNOSTIC LANDSCAPE OF EMBRYONAL TUMORS WITH MULTI-LAYERED ROSETTES (ETMRs), A RARE BRAIN TUMOR REGISTRY (RBTC) STUDY. Neuro-Oncology, 2020, 22, iii327-iii328.	1.2	0
53	Canadian Pediatric Neuro-Oncology Standards of Practice. Frontiers in Oncology, 2020, 10, 593192.	2.8	13
54	Outcomes of BRAF V600E Pediatric Gliomas Treated With Targeted BRAF Inhibition. JCO Precision Oncology, 2020, 4, 561-571.	3.0	62

#	ARTICLE	IF	CITATIONS
55	MR imaging features of diffuse intrinsic pontine glioma and relationship to overall survival: report from the International DIPG Registry. <i>Neuro-Oncology</i> , 2020, 22, 1647-1657.	1.2	51
56	Pattern of Relapse and Treatment Response in WNT-Activated Medulloblastoma. <i>Cell Reports Medicine</i> , 2020, 1, 100038.	6.5	24
57	Bridging the treatment gap in infant medulloblastoma: molecularly informed outcomes of a globally feasible regimen. <i>Neuro-Oncology</i> , 2020, 22, 1873-1881.	1.2	12
58	Integrated Molecular and Clinical Analysis of 1,000 Pediatric Low-Grade Gliomas. <i>Cancer Cell</i> , 2020, 37, 569-583.e5.	16.8	244
59	Clinical impact of combined epigenetic and molecular analysis of pediatric low-grade gliomas. <i>Neuro-Oncology</i> , 2020, 22, 1474-1483.	1.2	39
60	Intracranial growing teratoma syndrome (iGTS): an international case series and review of the literature. <i>Journal of Neuro-Oncology</i> , 2020, 147, 721-730.	2.9	21
61	The effect of mTOR inhibition on obstructive hydrocephalus in patients with tuberous sclerosis complex (TSC) related subependymal giant cell astrocytoma (SEGA). <i>Journal of Neuro-Oncology</i> , 2020, 147, 731-736.	2.9	8
62	Symptom interval and treatment burden for patients with malignant central nervous system germ cell tumours. <i>Archives of Disease in Childhood</i> , 2020, 105, 247-252.	1.9	12
63	The role of tumor markers for relapse detection in central nervous system non-germinomatous germ cell tumors (CNS-NGGCT): A pool analysis of cooperative group clinical trials.. <i>Journal of Clinical Oncology</i> , 2020, 38, 2503-2503.	1.6	0
64	DIPG-20. DETERMINATION AND MANAGEMENT OF HYDROCEPHALUS IN PATIENTS WITH DIPG, AN INSTITUTIONAL EXPERIENCE. <i>Neuro-Oncology</i> , 2020, 22, iii291-iii291.	1.2	0
65	GCT-33. A PHASE 2 TRIAL OF RESPONSE-BASED RADIATION THERAPY FOR PATIENTS WITH LOCALIZED CENTRAL NERVOUS SYSTEM GERM CELL TUMORS: A CHILDREN'S ONCOLOGY GROUP (COG) STUDY. IMPACT OF RAPID CENTRAL RADIOTHERAPY REVIEW ON RADIOTHERAPY QUALITY AND PATTERN OF FAILURE FOR NON-GERMINOMATOUS GERM CELL TUMORS. <i>Neuro-Oncology</i> , 2020, 22, iii334-iii334.	1.2	0
66	GCT-21. CENTRAL NERVOUS SYSTEM GERMINOMA - PONDERING THE NEXT STEPS. <i>Neuro-Oncology</i> , 2020, 22, iii332-iii332.	1.2	0
67	DIPG-74. RE-IRRADIATION OF DIPG: DATA FROM THE INTERNATIONAL DIPG REGISTRY. <i>Neuro-Oncology</i> , 2020, 22, iii301-iii302.	1.2	0
68	DIPG-55. PATTERNS OF CEREBROSPINAL FLUID DIVERSION AND SURVIVAL IN CHILDREN WITH DIFFUSE INTRINSIC PONTINE GLIOMA: A REPORT FROM THE INTERNATIONAL DIPG REGISTRY. <i>Neuro-Oncology</i> , 2020, 22, iii297-iii298.	1.2	0
69	LINC-21. SURVEY ON THE RESOURCES AVAILABLE FOR PEDIATRIC NEURO-ONCOLOGY IN CHILE, SOUTH AMERICA. <i>Neuro-Oncology</i> , 2020, 22, iii382-iii382.	1.2	0
70	MBCL-26. FACTORS ASSOCIATED WITH LONGER SURVIVAL AFTER FIRST RECURRENCE IN MEDULLOBLASTOMA BY MOLECULAR SUBGROUP AFTER RISK-BASED INITIAL THERAPY. <i>Neuro-Oncology</i> , 2020, 22, iii394-iii394.	1.2	0
71	LINC-18. FOLLOW-UP EVALUATION OF A WEB-BASED PEDIATRIC BRAIN TUMOR BOARD IN LATIN AMERICA. <i>Neuro-Oncology</i> , 2020, 22, iii381-iii382.	1.2	0
72	DIPG-46. NON-DIPG PATIENTS ENROLLED IN THE INTERNATIONAL DIPG REGISTRY: HISTOPATHOLOGIC EVALUATION OF CENTRAL NEURO-IMAGING REVIEW. <i>Neuro-Oncology</i> , 2020, 22, iii295-iii296.	1.2	0

#	ARTICLE	IF	CITATIONS
73	LINC-10. SIOP PODC ADAPTED TREATMENT GUIDELINES FOR CRANIOPHARYNGIOMA IN LOW- AND MIDDLE-INCOME SETTINGS. <i>Neuro-Oncology</i> , 2020, 22, iii379-iii380.	1.2	0
74	GCT-41. RESPONSE-BASED RADIATION THERAPY IN PATIENTS WITH NEWLY DIAGNOSED CENTRAL NERVOUS SYSTEM LOCALIZED GERMINOMA: A CHILDREN'S ONCOLOGY GROUP (COG) PROSPECTIVE PHASE 2 CLINICAL TRIAL. <i>Neuro-Oncology</i> , 2020, 22, iii336-iii336.	1.2	5
75	GCT-42. CLINICAL CHARACTERISTICS OF LOCALIZED CENTRAL NERVOUS SYSTEM NON-GERMINOMATOUS GERM CELL TUMORS (NGGCT) PATIENTS ENROLLED ON ACNS1123 WITH RELAPSE: A CHILDREN'S ONCOLOGY GROUP (COG) STUDY. <i>Neuro-Oncology</i> , 2020, 22, iii336-iii336.	1.2	0
76	QOL-09. WHOLE-BRAIN WHITE MATTER NETWORK CONNECTIVITY IS DISRUPTED BY PEDIATRIC BRAIN TUMOR TREATMENT. <i>Neuro-Oncology</i> , 2020, 22, iii432-iii432.	1.2	1
77	RARE-09. PRESERVATION OF ENDOCRINE FUNCTION AFTER OMMAYA RESERVOIR INSERTION IN CHILDREN WITH CYSTIC CRANIOPHARYNGIOMA. <i>Neuro-Oncology</i> , 2020, 22, iii443-iii443.	1.2	0
78	GCT-75. ISOLATED PITUITARY STALK THICKENING. <i>Neuro-Oncology</i> , 2020, 22, iii343-iii343.	1.2	0
79	LGG-55. OUTCOME OF BRAF V600E PEDIATRIC GLIOMAS TREATED WITH TARGETED BRAF INHIBITION. <i>Neuro-Oncology</i> , 2020, 22, iii377-iii377.	1.2	0
80	GCT-23. MULTI-INSTITUTIONAL ANALYSIS OF TREATMENT MODALITIES IN BASAL GANGLIA AND THALAMIC GERMINOMA. <i>Neuro-Oncology</i> , 2020, 22, iii332-iii332.	1.2	0
81	NIMG-31. NON-DIPG PATIENTS ENROLLED IN THE INTERNATIONAL DIPG REGISTRY: HISTOPATHOLOGIC EVALUATION OF CENTRAL NEURO-IMAGING REVIEW. <i>Neuro-Oncology</i> , 2020, 22, ii154-ii154.	1.2	0
82	EPID-26. CLINICAL AND HISTOLOGICAL CHARACTERIZATION OF PRIMARY CENTRAL NERVOUS SYSTEM SARCOMA IN PEDIATRICS. A SINGLE INSTITUTION EXPERIENCE IN A MIDDLE-INCOME COUNTRY. <i>Neuro-Oncology</i> , 2020, 22, ii84-ii84.	1.2	0
83	Redefining Ventricular Target Volume in Germinoma: Is Inclusion of Temporal Horns Necessary?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 852-858.	0.8	7
84	“Not all that glitters is gold” insights from the Far East and how to solve a conundrum. <i>Neuro-Oncology</i> , 2019, 21, 1490-1492.	1.2	1
85	Re-irradiation for children with recurrent medulloblastoma in Toronto, Canada: a 20-year experience. <i>Journal of Neuro-Oncology</i> , 2019, 145, 107-114.	2.9	18
86	Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas. <i>Nature Communications</i> , 2019, 10, 4343.	12.8	200
87	Phase II Trial of Response-Based Radiation Therapy for Patients With Localized CNS Nongerminomatous Germ Cell Tumors: A Children's Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 3283-3290.	1.6	78
88	Diffuse intrinsic pontine glioma ventricular peritoneal shunt metastasis: a case report and literature review. <i>Child's Nervous System</i> , 2019, 35, 861-864.	1.1	9
89	Repeat irradiation for children with supratentorial high-grade glioma. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27881.	1.5	14
90	LGG-07. CLINICAL FEATURES OF NON-CANONICAL MOLECULAR DRIVERS IN PLGG; AN UPDATE FROM THE INTERNATIONAL PLGG TASKFORCE. <i>Neuro-Oncology</i> , 2019, 21, ii100-ii100.	1.2	0

#	ARTICLE	IF	CITATIONS
91	DIPG-36. CLINICAL, RADIOLOGICAL, AND HISTO-MOLECULAR CHARACTERISTICS OF DIFFUSE INTRINSIC PONTINE GLIOMA IN PATIENTS WHO SURVIVE LESS THAN 3 MONTHS FROM DIAGNOSIS: A REPORT FROM THE INTERNATIONAL DIPG REGISTRY. <i>Neuro-Oncology</i> , 2019, 21, ii76-ii77.	1.2	0
92	Are we friends? Best friend nominations in pediatric brain tumor survivors and associated factors. <i>Supportive Care in Cancer</i> , 2019, 27, 4237-4244.	2.2	16
93	Survival and functional outcomes of molecularly defined childhood posterior fossa ependymoma: Cure at a cost. <i>Cancer</i> , 2019, 125, 1867-1876.	4.1	49
94	LGG-16. PREDICTORS OF OUTCOME IN BRAF-V600E PEDIATRIC GLIOMAS TREATED WITH BRAF INHIBITORS: A REPORT FROM THE PLGG TASKFORCE. <i>Neuro-Oncology</i> , 2019, 21, ii102-ii102.	1.2	0
95	The Latin American Brain Tumor Board teleconference: results of a web-based survey to evaluate participant experience utilizing this resource. <i>Child's Nervous System</i> , 2019, 35, 257-265.	1.1	13
96	Craniospinal irradiation as part of re-irradiation for children with recurrent intracranial ependymoma. <i>Neuro-Oncology</i> , 2019, 21, 547-557.	1.2	32
97	Predicting social withdrawal, anxiety and depression symptoms in pediatric brain tumor survivors. <i>Journal of Psychosocial Oncology</i> , 2019, 37, 22-36.	1.2	15
98	End-of-life care of children with diffuse intrinsic pontine glioma. <i>Journal of Neuro-Oncology</i> , 2018, 138, 147-153.	2.9	5
99	Long-term visual outcomes of craniopharyngioma in children. <i>Journal of Neuro-Oncology</i> , 2018, 137, 645-651.	2.9	39
100	Reirradiation in patients with diffuse intrinsic pontine gliomas: The Canadian experience. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26988.	1.5	51
101	Video-Teleconferencing in Pediatric Neuro-Oncology: Ten Years of Experience. <i>Journal of Global Oncology</i> , 2018, 4, 1-7.	0.5	14
102	Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries. <i>Journal of Clinical Oncology</i> , 2018, 36, 1963-1972.	1.6	250
103	GERM-23. INTRACRANIAL GROWING TERATOMA SYNDROME (IGTS): AN INTERNATIONAL RETROSPECTIVE STUDY. <i>Neuro-Oncology</i> , 2018, 20, i88-i88.	1.2	0
104	LGG-10. EPIGENETIC/GENETIC/MORPHOLOGIC ANALYSES REVEAL CLINICAL/PROGNOSTIC INSIGHT OF PEDIATRIC LOW GRADE GLIOMAS. <i>Neuro-Oncology</i> , 2018, 20, i106-i106.	1.2	0
105	RTHP-34. CRANIOSPINAL IRRADIATION (CSI) AS PART OF RE-IRRADIATION (RT2) FOR CHILDREN WITH RECURRENT INTRACRANIAL EPENDYMOMA. <i>Neuro-Oncology</i> , 2018, 20, vi232-vi232.	1.2	1
106	DEV-14. IMPACT OF A LATIN AMERICA-WIDE TELECONFERENCED BRAIN TUMOR BOARD. <i>Neuro-Oncology</i> , 2018, 20, i47-i48.	1.2	4
107	EPEN-31. SUBGROUP SPECIFIC LONG-TERM SURVIVAL AND NEUROCOGNITIVE OUTCOMES IN POSTERIOR FOSSA EPENDYMOMA (PFE). <i>Neuro-Oncology</i> , 2018, 20, i79-i79.	1.2	0
108	GERM-08. EARLIER RECOGNITION OF SYMPTOMS AND DIAGNOSIS MAY REDUCE TREATMENT AND LATE EFFECT BURDEN IN CHILDREN, TEENAGERS AND YOUNG ADULTS WITH INTRACRANIAL GERM CELL TUMOURS. <i>Neuro-Oncology</i> , 2018, 20, i84-i85.	1.2	0

#	ARTICLE	IF	CITATIONS
109	LGG-60. THE GENETIC LANDSCAPE OF PEDIATRIC LOW-GRADE GLIOMAS: INCIDENCE, PROGNOSIS AND RESPONSE TO THERAPY. <i>Neuro-Oncology</i> , 2018, 20, i117-i117.	1.2	1
110	TBIO-30. MOLECULAR LANDSCAPE AND CLINICAL CORRELATIONS OF CNS SARCOMAS. <i>Neuro-Oncology</i> , 2018, 20, i186-i186.	1.2	0
111	DIPG-69. CHARACTERISTICS OF PATIENTS <10 YEARS OF AGE WITH DIFFUSE INTRINSIC PONTINE GLIOMA: A REPORT FROM THE INTERNATIONAL DIPG REGISTRY. <i>Neuro-Oncology</i> , 2018, 20, i63-i63.	1.2	1
112	DIPG-23. BRAINSTEM RADIATION EXPOSURE CONFERS SUBSTANTIAL RISK OF DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) IN MEDULLOBLASTOMA SURVIVORS: A REPORT FROM THE INTERNATIONAL DIPG REGISTRY. <i>Neuro-Oncology</i> , 2018, 20, i53-i53.	1.2	0
113	DEV-07. THE LATIN-AMERICAN BRAIN TUMOR BOARD (LATB) TELECONFERENCE: RESULTS OF A WEB-BASED SURVEY TO EVALUATE PARTICIPANT EXPERIENCE AND THE PROGRAM. <i>Neuro-Oncology</i> , 2018, 20, i46-i46.	1.2	1
114	LGG-59. REMARKABLE OBJECTIVE RESPONSE AND FAVORABLE SURVIVAL FOR BRAF-V600E CHILDHOOD LOW-GRADE GLIOMAS TO BRAF INHIBITORS COMPARED CONVENTIONAL CHEMOTHERAPY. <i>Neuro-Oncology</i> , 2018, 20, i117-i117.	1.2	0
115	Biological material collection to advance translational research and treatment of children with CNS tumours: position paper from the SIOPE Brain Tumour Group. <i>Lancet Oncology</i> , The, 2018, 19, e419-e428.	10.7	16
116	GERM-15. A PHASE 2 TRIAL OF RESPONSE-BASED RADIATION THERAPY FOR PATIENTS WITH LOCALIZED CENTRAL NERVOUS SYSTEM GERM CELL TUMORS (CNS GCT): A CHILDREN'S ONCOLOGY GROUP (COG) STUDY. <i>Neuro-Oncology</i> , 2018, 20, i86-i86.	1.2	4
117	Medulloblastoma therapy generates risk of a poorly-prognostic H3 wild-type subgroup of diffuse intrinsic pontine glioma: a report from the International DIPG Registry. <i>Acta Neuropathologica Communications</i> , 2018, 6, 67.	5.2	12
118	DIPG-70. CLINICAL, RADIOLOGICAL, PATHOLOGICAL AND MOLECULAR CHARACTERISTICS OF CHILDREN <3 YEARS WITH DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG): A REPORT FROM THE INTERNATIONAL DIPG REGISTRY. <i>Neuro-Oncology</i> , 2018, 20, i63-i63.	1.2	0
119	Exercise training for neural recovery in a restricted sample of pediatric brain tumor survivors: a controlled clinical trial with crossover of training versus no training. <i>Neuro-Oncology</i> , 2017, 19, now177.	1.2	73
120	The international diffuse intrinsic pontine glioma registry: an infrastructure to accelerate collaborative research for an orphan disease. <i>Journal of Neuro-Oncology</i> , 2017, 132, 323-331.	2.9	27
121	The clinical significance of equivocal findings on spinal MRI in children with medulloblastoma. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26472.	1.5	9
122	Determinants of social competence in pediatric brain tumor survivors who participated in an intervention study. <i>Supportive Care in Cancer</i> , 2017, 25, 2891-2898.	2.2	13
123	Review of management and morbidity of pediatric craniopharyngioma patients in a low-middle-income country: a 12-year experience. <i>Child's Nervous System</i> , 2017, 33, 941-950.	1.1	14
124	Intertumoral Heterogeneity within Medulloblastoma Subgroups. <i>Cancer Cell</i> , 2017, 31, 737-754.e6.	16.8	836
125	Determinants of quality of life outcomes for survivors of pediatric brain tumors. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26481.	1.5	18
126	Contemporary survival endpoints: an International Diffuse Intrinsic Pontine Glioma Registry study. <i>Neuro-Oncology</i> , 2017, 19, 1279-1280.	1.2	93

#	ARTICLE	IF	CITATIONS
127	Intracystic interferon-alpha in pediatric craniopharyngioma patients-reply. <i>Neuro-Oncology</i> , 2017, 19, 1420-1421.	1.2	4
128	Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas. <i>Journal of Clinical Oncology</i> , 2017, 35, 2934-2941.	1.6	232
129	Molecular alterations to predict survival and response to chemotherapy of pediatric low-grade glioma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 10503-10503.	1.6	0
130	Neurocognitive outcome in children with sensorineural hearing loss after treatment of malignant embryonal brain tumors.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2029-2029.	1.6	0
131	GC-17THE CHILDREN'S ONCOLOGY GROUP (COG) CURRENT TREATMENT APPROACH FOR CHILDREN WITH NEWLY DIAGNOSED CENTRAL NERVOUS SYSTEM (CNS) LOCALIZED GERMINOMA (ACNS1123 STRATUM 2). <i>Neuro-Oncology</i> , 2016, 18, iii45.4-iii46.	1.2	7
132	RA-10SUBTLE FINDINGS ON SPINAL MRIs IN CHILDREN NEWLY DIAGNOSED WITH MEDULLOBLASTOMA. <i>Neuro-Oncology</i> , 2016, 18, iii166.5-iii167.	1.2	0
133	CMS-03RISK FACTORS FOR LONG TERM SPEECH DEFICITS IN CHILDREN WITH CEREBELLAR MUTISM SYNDROME. <i>Neuro-Oncology</i> , 2016, 18, iii16.3-iii16.	1.2	0
134	Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors. <i>Cancer Cell</i> , 2016, 30, 891-908.	16.8	191
135	Paediatric cancer stage in population-based cancer registries: the Toronto consensus principles and guidelines. <i>Lancet Oncology</i> , The, 2016, 17, e163-e172.	10.7	56
136	Targeted detection of genetic alterations reveal the prognostic impact of H3K27M and MAPK pathway aberrations in paediatric thalamic glioma. <i>Acta Neuropathologica Communications</i> , 2016, 4, 93.	5.2	100
137	Intellectual Outcome in Molecular Subgroups of Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 4161-4170.	1.6	72
138	Phase II Weekly Vinblastine for Chemotherapy-Naïve Children With Progressive Low-Grade Glioma: A Canadian Pediatric Brain Tumor Consortium Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 3537-3543.	1.6	157
139	CMS-09BEHAVIOR AND TEMPERAMENT IN CHILDREN TREATED FOR PEDIATRIC MEDULLOBLASTOMA WITH POSTOPERATIVE CEREBELLAR MUTISM SYNDROME. <i>Neuro-Oncology</i> , 2016, 18, iii17.4-iii17.	1.2	0
140	Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. <i>Journal of Clinical Oncology</i> , 2016, 34, 2468-2477.	1.6	160
141	Clinical and treatment factors determining long-term outcomes for adult survivors of childhood low-grade glioma: A population-based study. <i>Cancer</i> , 2016, 122, 1261-1269.	4.1	109
142	Medulloblastoma subgroup-specific outcomes in irradiated children: who are the true high-risk patients?. <i>Neuro-Oncology</i> , 2016, 18, 291-297.	1.2	112
143	Divergent clonal selection dominates medulloblastoma at recurrence. <i>Nature</i> , 2016, 529, 351-357.	27.8	266
144	Outcomes of children with central nervous system germinoma treated with multi-agent chemotherapy followed by reduced radiation. <i>Journal of Neuro-Oncology</i> , 2016, 127, 173-180.	2.9	64

#	ARTICLE	IF	CITATIONS
145	Relationship of BRAF V600E and associated secondary mutations on survival rate and response to conventional therapies in childhood low-grade glioma.. Journal of Clinical Oncology, 2016, 34, 10509-10509.	1.6	3
146	Re-irradiation for relapsed paediatric ependymoma.. Journal of Clinical Oncology, 2016, 34, 10565-10565.	1.6	1
147	Imaging of metastatic medulloblastoma in the molecular era.. Journal of Clinical Oncology, 2016, 34, e22003-e22003.	1.6	0
148	When a child dies: pediatric oncologists' follow-up practices with families after the death of their child. Psycho-Oncology, 2015, 24, 1626-1631.	2.3	15
149	Dose-level response rates of mTOR inhibition in tuberous sclerosis complex related subependymal giant cell astrocytoma. Pediatric Blood and Cancer, 2015, 62, 1754-1760.	1.5	16
150	Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss. Nature Genetics, 2015, 47, 263-266.	21.4	109
151	Challenges Faced by Pediatric Oncology Fellows When Patients Die During Their Training. Journal of Oncology Practice, 2015, 11, e182-e189.	2.5	19
152	Consensus on the management of intracranial germ-cell tumours. Lancet Oncology, The, 2015, 16, e470-e477.	10.7	173
153	Pathological Findings of a Subependymal Giant Cell Astrocytoma Following Treatment With Rapamycin. Pediatric Neurology, 2015, 53, 238-242.e1.	2.1	6
154	Pulmonary Function After Treatment for Embryonal Brain Tumors on SJMB03 That Included Craniospinal Irradiation. International Journal of Radiation Oncology Biology Physics, 2015, 93, 47-53.	0.8	14
155	Outcome of neurofibromatosis type 1 patients treated with first line vinblastine for optic pathway gliomas: A Canadian multicenter study.. Journal of Clinical Oncology, 2015, 33, 2019-2019.	1.6	1
156	Bridging the Distance in the Caribbean: Telemedicine as a means to build capacity for care in paediatric cancer and blood disorders. Studies in Health Technology and Informatics, 2015, 209, 1-8.	0.3	15
157	Histopathological spectrum of paediatric diffuse intrinsic pontine glioma: diagnostic and therapeutic implications. Acta Neuropathologica, 2014, 128, 573-581.	7.7	258
158	Predictors of Symptoms and Site of Death in Pediatric Palliative Patients With Cancer at End of Life. American Journal of Hospice and Palliative Medicine, 2014, 31, 548-552.	1.4	17
159	Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nature Genetics, 2014, 46, 451-456.	21.4	525
160	Phase 2 study of safety and efficacy of nimotuzumab in pediatric patients with progressive diffuse intrinsic pontine glioma. Neuro-Oncology, 2014, 16, 1554-1559.	1.2	44
161	DETAILED MOLECULAR CHARACTERISATION OF DIFFUSE INTRINSIC PONTINE GLIOMAS IDENTIFIES THREE MOLECULAR SUBGROUPS AND A NOVEL CANCER DRIVER, ACVR1. Neuro-Oncology, 2014, 16, iii26-iii27.	1.2	0
162	Concordance between the chang and the International Society of Pediatric Oncology (<sc>SIOP</sc>) ototoxicity grading scales in patients treated with cisplatin for medulloblastoma. Pediatric Blood and Cancer, 2014, 61, 601-605.	1.5	36

#	ARTICLE	IF	CITATIONS
163	Targeted Therapy in Pediatric Low-Grade Glioma. Current Neurology and Neuroscience Reports, 2014, 14, 441.	4.2	16
164	Weekly vinblastine in chemotherapy-naïve children with unresectable or progressive low grade glioma: A Canadian cooperative study.. Journal of Clinical Oncology, 2013, 31, 10029-10029.	1.6	2
165	K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathologica, 2012, 124, 439-447.	7.7	799
166	Intracystic Therapies for Cystic Craniopharyngioma in Childhood. Frontiers in Endocrinology, 2012, 3, 39.	3.5	86
167	Favorable outcome with conservative treatment for children with low grade brainstem tumors. Pediatric Blood and Cancer, 2012, 58, 556-560.	1.5	33
168	Post mortem examinations in diffuse intrinsic pontine glioma: challenges and chances. Journal of Neuro-Oncology, 2011, 101, 75-81.	2.9	52
169	Challenges in management of patients with intracranial germ cell tumor and diabetes insipidus treated with cisplatin and/or ifosfamide based chemotherapy. Journal of Neuro-Oncology, 2010, 97, 393-399.	2.9	34
170	Inherent diagnostic and treatment challenges in germinoma of the basal ganglia: a case report and review of the literature. Journal of Neuro-Oncology, 2008, 88, 309-314.	2.9	26
171	Assessment of chemotherapeutic response in children with proptosis due to optic nerve glioma. Child's Nervous System, 2008, 24, 707-712.	1.1	10
172	Diffuse brainstem glioma in children: critical review of clinical trials. Lancet Oncology, The, 2006, 7, 241-248.	10.7	547
173	Limited-field radiation for bifocal germinoma. International Journal of Radiation Oncology Biology Physics, 2006, 65, 486-492.	0.8	86
174	Basal ganglia germinoma in children with associated ipsilateral cerebral and brain stem hemiatrophy. Pediatric Radiology, 2006, 36, 325-330.	2.0	70
175	Role of spinal MRI in the follow-up of children treated for medulloblastoma. Cancer, 2006, 107, 1340-1347.	4.1	23
176	Vascularity and angiogenesis as predictors of growth in optic pathway/hypothalamic gliomas. Journal of Neurosurgery: Pediatrics, 2006, 104, 314-320.	1.3	30
177	Prognostic factors related to overall survival in adolescent and young adults with medulloblastoma: a systematic review. Neuro-Oncology Advances, 0, , .	0.7	3